JATT Acquisition Corp
JATT-UN
New York Stock Exchange10.31
USD
- -
- -
JATT Acquisition Corp
JATT-UN
(New York Stock Exchange)
Recent
price
10.31
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- JATT Acquisition Corp (NYSE: JATT-UN) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities, primarily in the life sciences sector; it offers no current products or services beyond its SPAC structure, which includes Class A ordinary shares and redeemable warrants traded separately under symbols JATT and JATT WS. Founded in 2021 and headquartered in Grand Cayman, Cayman Islands, the company raised $138 million in its initial public offering in July 2021, with proceeds held in trust for deployment in a target acquisition. In March 2023, JATT completed a business combination with Zura Bio Limited through shareholder approval on March 16, 2023, and closing on March 20, 2023, resulting in a name change to Zura Bio Limited, transfer of listing to Nasdaq under ticker ZURA, and provision of up to $65 million in net proceeds to fund Zura Bio's clinical-stage immunology pipeline including ZB-168 and torudokimab; post-merger, JATT-UN units represent residual interests in the predecessor entity, with no independent operations as the combined company advances dual-pathway biologics for immune and inflammatory disorders targeting markets in the United States and Europe.